BDSI
NASDAQBioDelivery Sciences International Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)SC 13G/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
- PRGenenta Provides First Half 2022 Business Update and Financial ResultsCurrent dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.
- PRGenenta Announces Nomination of Mark A. Sirgo as Chair35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan
- SECSEC Form 15-12B filed by BioDelivery Sciences International Inc.15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
- NEWSOverview Of Value Stocks In The Healthcare SectorWhat are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. The following stocks are considered to be notable value stocks in the healthcare sector: BioDelivery Sciences Intl (NASDAQ:BDSI) - P/E: 6.82 Innoviva (NASDAQ:INVA) - P/E: 6.83 BioNTech (NASDAQ:BNTX) - P/E: 4.74 Regeneron Pharmaceuticals (NASDAQ:REGN) - P/E: 9.45 Bio-Rad Laborato
- SECSEC Form EFFECT filed by BioDelivery Sciences International Inc.EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
- SECSEC Form S-8 POS filed by BioDelivery Sciences International Inc.S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
- SECSEC Form POS AM filed by BioDelivery Sciences International Inc.POS AM - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
- INSIDERSEC Form 4: Watson W. Mark disposed of 90,663 shares, closing all direct ownership in the company to satisfy tax liability4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4 filed by Vollins James (withholding tax)4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Singh Vanila disposed of 35,851 shares, closing all direct ownership in the company to satisfy withholding tax4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Smith Thomas B disposed of 52,530 shares, closing all direct ownership in the company (withholding obligation)4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Sirgo Mark A disposed of 1,166,866 shares, closing all direct ownership in the company (for tax liability)4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Plesha Scott M. disposed of 345,127 shares, closing all direct ownership in the company to satisfy withholding obligation4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Kotler Kevin disposed of 7,588,395 shares4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4 filed by Golubieski John to cover withholding tax4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Greenleaf Peter disposed of 105,034 shares, closing all direct ownership in the company to cover withholding tax4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Davis Todd C disposed of 252,207 shares, closing all direct ownership in the company to satisfy withholding obligation4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- INSIDERSEC Form 4: Bailey Jeffrey Allen disposed of 105,133 shares, closing all direct ownership in the company to cover taxes4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- SECBioDelivery Sciences International Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
- PRCollegium Completes the Acquisition of BDSISTOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio
- SECSEC Form SC 14D9/A filed by BioDelivery Sciences International Inc. (Amendment)SC 14D9/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
- SECSEC Form SC 14D9/A filed by BioDelivery Sciences International Inc. (Amendment)SC 14D9/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
- INSIDERSEC Form 4: Bailey Jeffrey Allen converted options into 5,333 shares, increasing direct ownership by 5% to 105,133 units4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
- SECSEC Form 10-K filed by BioDelivery Sciences International Inc.10-K - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
BDSI FAQ
6 questionsWhat does BioDelivery Sciences International Inc. do?
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence...Where does BDSI stock trade?
BioDelivery Sciences International Inc. (BDSI) is listed on NASDAQ.What sector and industry is BDSI in?
BioDelivery Sciences International Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BDSI?
BioDelivery Sciences International Inc. has had 4 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $560.00 price target on 2022-02-15. Recent price targets range from $450.00 to $600.00.What companies are similar to BDSI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BDSI side-by-side with any of them on Quantisnow.How can I track BDSI on Quantisnow?
Quantisnow aggregates BioDelivery Sciences International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDSI to receive live email and push alerts on every new disclosure.